1. Home
  2. ATR vs PCVX Comparison

ATR vs PCVX Comparison

Compare ATR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AptarGroup Inc.

ATR

AptarGroup Inc.

HOLD

Current Price

$127.17

Market Cap

8.0B

Sector

Industrials

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$61.32

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATR
PCVX
Founded
1992
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
7.0B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
ATR
PCVX
Price
$127.17
$61.32
Analyst Decision
Buy
Strong Buy
Analyst Count
9
11
Target Price
★ $162.25
$117.30
AVG Volume (30 Days)
430.8K
★ 3.6M
Earning Date
10-29-2026
11-10-2026
Dividend Yield
★ 1.51%
N/A
EPS Growth
★ 6.51
N/A
EPS
★ 2.48
N/A
Revenue
★ $3,777,181,000.00
N/A
Revenue This Year
$5.19
N/A
Revenue Next Year
$3.41
N/A
P/E Ratio
$51.31
★ N/A
Revenue Growth
★ 5.42
N/A
52 Week Low
$103.23
$39.87
52 Week High
$146.24
$90.75

Technical Indicators

Market Signals
Indicator
ATR
PCVX
Relative Strength Index (RSI) 57.32 47.75
Support Level $119.45 $52.91
Resistance Level $127.24 $63.08
Average True Range (ATR) 2.07 3.56
MACD 0.73 -0.81
Stochastic Oscillator 78.84 16.90

Price Performance

Historical Comparison
ATR
PCVX

About ATR AptarGroup Inc.

Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: